Gene Expression Profiles Predict Infliximab Treatment Response in Patients with Treatment-Resistant Depression
Ontology highlight
ABSTRACT: To further explore predictors and targets of response to infliximab, differential gene expression was examined at baseline and after 6 and 24 hours and 2 weeks after the first infusion of infliximab in TRD patients who were infliximab responders versus nonresponders, and compared to placebo-treated patients. In a recent clinical trial, the TNF antagonist infliximab was found to reduce depressive symptoms compared to placebo but only in patients with increased inflammation as reflected by a CRP >5 mg/L. To further explore predictors and targets of response to infliximab, differential gene expression was examined at baseline and after 6 and 24 hours and 2 weeks after the first infusion of infliximab in TRD patients who were infliximab responders versus nonresponders, and compared to placebo-treated patients.
ORGANISM(S): Homo sapiens
SUBMITTER: Divya Mehta
PROVIDER: E-GEOD-45468 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA